Males who are trying to conceive should be counselled on the post-finasteride syndrome.

An increasing number of compelling reports of the post-finasteride syndrome in clinical literature has resulted in the update of the labelling of finasteride to include the risk of depression and persistent sexual dysfunction, by regulatory agencies such as the Swedish Medical Products Agency, Medicine Health Care Products Regulatory Agency and the US FDA. Males who are trying to conceive should be counselled on the post-finasteride syndrome.

—Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity: Andrology, July 25, 2022